Ligand Expands Portfolio With XOMA Royalty AcquisitionThis move is expected to bolster Ligand’s long-term growth, adding new commercial products and enhancing its position as a leading biopharma royalty aggregator.Deal consideration includes $39.00 per share in cash, for a total equity value of approximately $739 million.XOMA Royalty stockholders are expected to separately receive one non-transferable Contingent Value Right per share entitling the holder to receive a portion of 75% of the net proceeds that ...